Literature DB >> 23958798

Rheumatoid arthritis: role for infliximab uncertain as targeted DMARD combinations achieve effective disease control.

Emma Leah.   

Abstract

Entities:  

Year:  2013        PMID： 23958798     DOI： 10.1038/nrrheum.2013.132

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Authors:  Vappu Rantalaiho; Hannu Kautiainen; Markku Korpela; Pekka Hannonen; Oili Kaipiainen-Seppänen; Timo Möttönen; Markku Kauppi; Anna Karjalainen; Kari Laiho; Leena Laasonen; Mikko Hakola; Ritva Peltomaa; Marjatta Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2013-08-01       Impact factor: 19.103

2.  Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).

Authors:  J L Nam; E Villeneuve; E M A Hensor; P G Conaghan; H I Keen; M H Buch; A K Gough; M J Green; P S Helliwell; A M Keenan; A W Morgan; M Quinn; R Reece; D M van der Heijde; R J Wakefield; P Emery
Journal:  Ann Rheum Dis       Date:  2013-08-02       Impact factor: 19.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.